We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I’d buy this growing FTSE 100 stock in this market weakness

This FTSE 100 (INDEXFTSE: UKX) firm is executing its growth strategy well in a market with a tailwind.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

When I think of the FTSE 100, Rentokil Initial (LSE: RTO) isn’t the first name I tend to remember, but maybe it should be. The company has been performing well over the past few years and the directors are focused on driving strong growth in a robust and expanding market.

I’m impressed by the firm’s record of growing its revenue, earnings and operating cash flow. Over six years, the dividend has risen more than 100%, which I think is a good litmus test of how effective the firm’s growth strategy is as it expands around the world. Roughly 90% of revenue comes from outside the UK with the firm operating in North America, Europe, Asia and the Pacific region, as well as in Britain.

Should you buy Rentokil Initial Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Consolidating a fragmented industry

The core driver of growth is the pest control operation, and the company sees itself as a consolidator in the sector as it thrusts into new territories across the globe. The industry is fragmented, according to the directors, which gives the firm the opportunity to grow by acquiring smaller businesses in areas that offer good growth potential. However, the company also enjoys leading positions in the hygiene services and interior landscaping sectors and states that its business model for profitable growth focuses on “compounding revenue, profit and cash growth through organic growth and M&A (mergers and acquisitions).” 

Today’s third-quarter trading update reveals that continuing revenue at constant currency exchange rates rose almost 12% compared to the equivalent period last year. Just over 4% came from organic growth and the rest from acquisitions. I don’t think I’ve come across a FTSE 100 firm that is as focused on its acquisition programme as Rentokil Initial appears to be. The company acquired 16 new bolt-on businesses in the period, 14 in its Pest Control division, one in the Hygiene division and one in Ambius, its interior landscaping division. Most of the takeovers were in emerging and growth markets.

A strong pipeline

To put the acquisition programme in perspective, the combined annualised revenues of all of the businesses acquired so far in 2018 in the year before Rentokil Initial bought them comes to just over £156m.  That compares to Rentokil Initial’s 2017 turnover of a little over £2.4bn, so the strategy doesn’t expose the firm to big risks. The purchases are small businesses, typically the best-run of several competing firms in an attractive market. Rentokil swoops in, makes an offer, and after it has been accepted applies all its know-how to expand from its initial toe-hold in the new market, which is typically in a fast-growing city somewhere in the world.

The company said in the report that “the M&A pipeline going into Q4 and 2019 remains strong.” And chief executive Andy Ransome said the company is “on track to meet expectations for the full year.”  City analysts following the firm have pencilled in a rise of around 5% in earnings this year and 11% in 2019, so we can expect more steady progress ahead. The shares are not cheap. Today’s share price throws up a forward price-to-earnings ratio close to 22 for 2019, but the business is executing its growth strategy well in a market with a tailwind. I think it deserves its rating and is a good candidate for a long-term hold in my portfolio.  

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Image of happy young people man and woman in basic clothing thinking and touching chin while looking aside isolated over yellow background
Investing Articles

I asked ChatGPT where Greggs shares might go next and it said… 

Harvey Jones is in two minds about the outlook for Greggs shares and called in artificial intelligence for its view.…

Read more »

Happy senior couple hugging and enjoying retirement at home
Investing Articles

Up 1,320% in 5 years — now check out the Rolls-Royce share price forecast for August 2027

The Rolls-Royce share price has completely smashed it but the big question is where it goes in future. Harvey Jones…

Read more »

Elderly, couple hiking and bird watching with adventure outdoor, hike together and fitness for active lifestyle. Nature, trekking and senior man pointing and woman with binocular, freedom and travel.
Investing Articles

After it rocketed to a 19-year high, here’s what the experts say about the Barclays share price outlook…

Harvey Jones examines why the Barclays share price has been flying lately and what broker forecasts suggest for the year…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

I asked ChatGPT if the Lloyds share price will crash in 2026. It said…

What probability of a Lloyds share price crash does the world's leading artificial intelligence chatbot give? The answer may surprise…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Will this week bring more bad news for BP shareholders?

The retreat in the oil price is good news for the global economy but bad news for BP shares. Harvey…

Read more »

Image of happy young people man and woman in basic clothing thinking and touching chin while looking aside isolated over yellow background
Investing Articles

How do I maximise the value of my Stocks and Shares ISA over the next 5 years?

Edward Sheldon has money in a Stocks and Shares ISA. And he wants to see the value of his portfolio…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
US Stock

I asked ChatGPT where the SpaceX share price will be at the end of 2026. It said…

Jon Smith decides to get another opinion on the direction of travel for the SpaceX share price, and ChatGPT is…

Read more »

Investing Articles

Are Scottish Mortgage shares an unmissable buy after the SpaceX stock crash?

Harvey Jones wonders whether investors have been given an opportunity to buy Scottish Mortgage shares at a decent price, as…

Read more »